NO20064788L - Anti-myostatin-anistoffer - Google Patents
Anti-myostatin-anistofferInfo
- Publication number
- NO20064788L NO20064788L NO20064788A NO20064788A NO20064788L NO 20064788 L NO20064788 L NO 20064788L NO 20064788 A NO20064788 A NO 20064788A NO 20064788 A NO20064788 A NO 20064788A NO 20064788 L NO20064788 L NO 20064788L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- myostatin
- epitope
- anistoffer
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
Abstract
Sammendrag 0. nr. P60601579NO00 Det identifiseres en nøytraliserende epitop innen aminosyrene 40-64 av den mature form av human myostatin. Antistoffer som binder denne epitop faller innenfor rammen av oppfinnelsen og kan være murine, kimere eller humaniserte antistoffer, immunokonjugater av antistoffer eller antigenbindende fragmenter derav. Antistoffene ifølge oppfinnelsen er brukbare for å øke muskelmassen, å øke bendensiteten eller for behandling av forskjellige sykdommer i pattedyr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55545604P | 2004-03-23 | 2004-03-23 | |
US55962104P | 2004-04-05 | 2004-04-05 | |
PCT/US2005/009307 WO2005094446A2 (en) | 2004-03-23 | 2005-03-17 | Anti-myostatin antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064788L true NO20064788L (no) | 2006-12-05 |
Family
ID=35064367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064788A NO20064788L (no) | 2004-03-23 | 2006-10-23 | Anti-myostatin-anistoffer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070178095A1 (no) |
EP (1) | EP1733041B1 (no) |
JP (1) | JP4695133B2 (no) |
KR (1) | KR20060133049A (no) |
AT (1) | ATE557042T1 (no) |
AU (1) | AU2005227896B2 (no) |
BR (1) | BRPI0508716A (no) |
CA (1) | CA2558805C (no) |
EA (1) | EA014112B1 (no) |
ES (1) | ES2384176T3 (no) |
IL (1) | IL177956A (no) |
MX (1) | MXPA06010929A (no) |
NO (1) | NO20064788L (no) |
WO (1) | WO2005094446A2 (no) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7511012B2 (en) | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
TW200724548A (en) * | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
EP1968621A2 (en) * | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP5058261B2 (ja) * | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
BRPI0811317A2 (pt) | 2007-08-03 | 2015-01-27 | Summit Corp Plc | Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
HUP0800448A2 (en) * | 2008-07-21 | 2011-02-28 | Pecsi Tudomanyegyetem | Diagnosis of systemic diseases |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
FR2943249B1 (fr) * | 2009-03-18 | 2011-08-12 | Genethon | Utilisation de la decorine pour augmenter la masse musculaire |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
FR2982860B1 (fr) | 2011-11-18 | 2015-07-10 | Ass Fr Contre Les Myopathies | Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire |
RU2663141C2 (ru) * | 2012-01-20 | 2018-08-01 | Джензим Корпорейшн | Анти-cxcr3 антитела |
MX364738B (es) * | 2012-06-15 | 2019-05-03 | Pfizer | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos. |
CA2880649C (en) | 2012-08-01 | 2023-03-14 | Elizabeth MCNALLY | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
KR20230110836A (ko) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
CN104768969B (zh) | 2012-09-13 | 2021-04-16 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
EP3119432B1 (en) | 2014-03-19 | 2020-01-08 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
MX2017013267A (es) | 2015-04-15 | 2018-08-15 | Regeneron Pharma | Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). |
JP7141336B2 (ja) * | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
KR102306744B1 (ko) | 2016-06-17 | 2021-09-28 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
EP4218817A3 (en) * | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
MA52417A (fr) | 2018-03-01 | 2021-01-06 | Regeneron Pharma | Procédés de modification de composition corporelle |
EP3898672A1 (en) | 2018-12-18 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
CA2205007C (en) * | 1995-09-11 | 2010-12-14 | Masamichi Koike | Antibody against human interleukin-5 receptor .alpha. chain |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
DE69941116D1 (de) * | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
US6537781B1 (en) * | 1999-08-10 | 2003-03-25 | Idexx Laboratories, Inc. | Methods and compositions concerning canine interleukin 5 |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
-
2005
- 2005-03-17 US US10/593,810 patent/US20070178095A1/en not_active Abandoned
- 2005-03-17 KR KR1020067021903A patent/KR20060133049A/ko not_active Application Discontinuation
- 2005-03-17 BR BRPI0508716-3A patent/BRPI0508716A/pt not_active IP Right Cessation
- 2005-03-17 ES ES05734951T patent/ES2384176T3/es active Active
- 2005-03-17 EP EP05734951A patent/EP1733041B1/en not_active Revoked
- 2005-03-17 MX MXPA06010929A patent/MXPA06010929A/es active IP Right Grant
- 2005-03-17 AT AT05734951T patent/ATE557042T1/de active
- 2005-03-17 AU AU2005227896A patent/AU2005227896B2/en not_active Ceased
- 2005-03-17 JP JP2007505055A patent/JP4695133B2/ja not_active Expired - Fee Related
- 2005-03-17 EA EA200601752A patent/EA014112B1/ru not_active IP Right Cessation
- 2005-03-17 WO PCT/US2005/009307 patent/WO2005094446A2/en active Application Filing
- 2005-03-17 CA CA2558805A patent/CA2558805C/en not_active Expired - Fee Related
-
2006
- 2006-09-07 IL IL177956A patent/IL177956A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064788A patent/NO20064788L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007530551A (ja) | 2007-11-01 |
EP1733041B1 (en) | 2012-05-09 |
EP1733041A4 (en) | 2009-01-28 |
IL177956A0 (en) | 2006-12-31 |
EA200601752A1 (ru) | 2007-02-27 |
MXPA06010929A (es) | 2007-01-16 |
WO2005094446A3 (en) | 2005-12-22 |
JP4695133B2 (ja) | 2011-06-08 |
EA014112B1 (ru) | 2010-10-29 |
KR20060133049A (ko) | 2006-12-22 |
EP1733041A2 (en) | 2006-12-20 |
CA2558805C (en) | 2011-09-27 |
IL177956A (en) | 2010-11-30 |
US20070178095A1 (en) | 2007-08-02 |
ATE557042T1 (de) | 2012-05-15 |
WO2005094446A2 (en) | 2005-10-13 |
BRPI0508716A (pt) | 2007-08-07 |
AU2005227896B2 (en) | 2008-11-13 |
AU2005227896A1 (en) | 2005-10-13 |
ES2384176T3 (es) | 2012-07-02 |
CA2558805A1 (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064788L (no) | Anti-myostatin-anistoffer | |
WO2007044411A3 (en) | Anti-myostatin antibodies | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
NL301196I2 (nl) | inebilizumab | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
TN2009000383A1 (en) | Anti - sclerostin antibodies | |
DK3284753T3 (da) | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose | |
IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
WO2009135861A3 (en) | Humanized antibodies against human interferon-alpha | |
MX2022012182A (es) | Metodos de uso de anticuerpos anti-trem2. | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
CR20220047A (es) | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados | |
WO2003073982A3 (en) | Anti-interleukin-1 beta analogs | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
WO2007101021A3 (en) | Humanized anti-ghrelin antibodies | |
ZA202205813B (en) | Trpv1 epitopes and antibodies | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
TW200740845A (en) | Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue | |
CY1115979T1 (el) | Αντισωματα κατα της μυοστατινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |